Literature DB >> 22340730

Suppression of survival signalling pathways by the phosphatase PHLPP.

Audrey K O'Neill1, Matthew J Niederst, Alexandra C Newton.   

Abstract

The recently discovered pleckstrin homology (PH) domain leucine-rich repeat protein phosphatase (PHLPP) family is emerging as a central component in suppressing cell survival pathways. Originally discovered in a rational search for a phosphatase that directly dephosphorylates and inactivates Akt, PHLPP is now known to potently suppress cell survival both by inhibiting proliferative pathways and by promoting apoptotic pathways. In the first instance, PHLPP directly dephosphorylates a conserved regulatory site (termed the hydrophobic motif) on Akt, protein kinase C and S6 kinase, thereby terminating signalling by these pro-survival kinases. In the second instance, PHLPP dephosphorylates and thus activates the pro-apoptotic kinase Mst1, thereby promoting apoptosis. PHLPP is deleted in a large number of cancers and the genetic deletion of one isozyme in a PTEN (phosphatase and tensin homologue located on chromosome 1) +/- (or heterozygous) prostate cancer model results in increased tumourigenesis, underscoring the role of PHLPP as a tumour suppressor. This review summarizes the targets and cellular actions of PHLPP, with emphasis on its role as a tumour suppressor in the oncogenic phosphoinositide 3-kinase (PI3K)/Akt signalling cascade.
© 2012 The Authors Journal compilation © 2012 FEBS.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22340730      PMCID: PMC3770140          DOI: 10.1111/j.1742-4658.2012.08537.x

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  84 in total

1.  SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression.

Authors:  Zhihu Ding; Chang-Jiun Wu; Gerald C Chu; Yonghong Xiao; Dennis Ho; Jingfang Zhang; Samuel R Perry; Emma S Labrot; Xiaoqiu Wu; Rosina Lis; Yujin Hoshida; David Hiller; Baoli Hu; Shan Jiang; Hongwu Zheng; Alexander H Stegh; Kenneth L Scott; Sabina Signoretti; Nabeel Bardeesy; Y Alan Wang; David E Hill; Todd R Golub; Meir J Stampfer; Wing H Wong; Massimo Loda; Lorelei Mucci; Lynda Chin; Ronald A DePinho
Journal:  Nature       Date:  2011-02-02       Impact factor: 49.962

2.  Cutting edge: PHLPP regulates the development, function, and molecular signaling pathways of regulatory T cells.

Authors:  Scott J Patterson; Jonathan M Han; Rosa Garcia; Kiran Assi; Tianyan Gao; Audrey O'Neill; Alexandra C Newton; Megan K Levings
Journal:  J Immunol       Date:  2011-04-15       Impact factor: 5.422

3.  The de-ubiquitinase UCH-L1 is an oncogene that drives the development of lymphoma in vivo by deregulating PHLPP1 and Akt signaling.

Authors:  S Hussain; O Foreman; S L Perkins; T E Witzig; R R Miles; J van Deursen; P J Galardy
Journal:  Leukemia       Date:  2010-06-24       Impact factor: 11.528

Review 4.  Protein kinase signaling networks in cancer.

Authors:  John Brognard; Tony Hunter
Journal:  Curr Opin Genet Dev       Date:  2010-11-29       Impact factor: 5.578

5.  PHLPP1 splice variants differentially regulate AKT and PKCα signaling in hippocampal neurons: characterization of PHLPP proteins in the adult hippocampus.

Authors:  Travis C Jackson; Jonathan D Verrier; Susan Semple-Rowland; Ashok Kumar; Thomas C Foster
Journal:  J Neurochem       Date:  2010-09-28       Impact factor: 5.372

6.  Reduced expression of the tumor suppressor PHLPP1 enhances the antiapoptotic B-cell receptor signal in chronic lymphocytic leukemia B-cells.

Authors:  M Suljagic; L Laurenti; M Tarnani; M Alam; S N Malek; D G Efremov
Journal:  Leukemia       Date:  2010-09-23       Impact factor: 11.528

7.  mTOR-dependent regulation of PHLPP expression controls the rapamycin sensitivity in cancer cells.

Authors:  Jianyu Liu; Payton D Stevens; Tianyan Gao
Journal:  J Biol Chem       Date:  2010-12-22       Impact factor: 5.157

8.  Mislocalization of the E3 ligase, β-transducin repeat-containing protein 1 (β-TrCP1), in glioblastoma uncouples negative feedback between the pleckstrin homology domain leucine-rich repeat protein phosphatase 1 (PHLPP1) and Akt.

Authors:  Noel A Warfel; Matt Niederst; Michael W Stevens; Paul M Brennan; Margaret C Frame; Alexandra C Newton
Journal:  J Biol Chem       Date:  2011-03-28       Impact factor: 5.157

9.  Discovery of small molecule inhibitors of the PH domain leucine-rich repeat protein phosphatase (PHLPP) by chemical and virtual screening.

Authors:  Emma Sierecki; William Sinko; J Andrew McCammon; Alexandra C Newton
Journal:  J Med Chem       Date:  2010-10-14       Impact factor: 7.446

10.  Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer.

Authors:  Brett S Carver; Caren Chapinski; John Wongvipat; Haley Hieronymus; Yu Chen; Sarat Chandarlapaty; Vivek K Arora; Carl Le; Jason Koutcher; Howard Scher; Peter T Scardino; Neal Rosen; Charles L Sawyers
Journal:  Cancer Cell       Date:  2011-05-17       Impact factor: 31.743

View more
  47 in total

1.  PHLPP2 Downregulation Contributes to Lung Carcinogenesis Following B[a]P/B[a]PDE Exposure.

Authors:  Haishan Huang; Xiaofu Pan; Honglei Jin; Yang Li; Lin Zhang; Caili Yang; Pei Liu; Ya Liu; Lili Chen; Jingxia Li; Junlan Zhu; Xingruo Zeng; Kai Fu; Guorong Chen; Jimin Gao; Chuanshu Huang
Journal:  Clin Cancer Res       Date:  2015-05-14       Impact factor: 12.531

2.  FANCI is a negative regulator of Akt activation.

Authors:  Xiaoshan Zhang; Xiaoyan Lu; Shamima Akhter; Maria-Magdalena Georgescu; Randy J Legerski
Journal:  Cell Cycle       Date:  2016       Impact factor: 4.534

3.  Transcription factor C/EBP-β induces tumor-suppressor phosphatase PHLPP2 through repression of the miR-17-92 cluster in differentiating AML cells.

Authors:  Y Yan; E A Hanse; K Stedman; J M Benson; X H Lowman; S Subramanian; A Kelekar
Journal:  Cell Death Differ       Date:  2016-02-12       Impact factor: 15.828

4.  Cytotoxic activity of the casein kinase 2 inhibitor CX-4945 against T-cell acute lymphoblastic leukemia: targeting the unfolded protein response signaling.

Authors:  F Buontempo; E Orsini; L R Martins; I Antunes; A Lonetti; F Chiarini; G Tabellini; C Evangelisti; C Evangelisti; F Melchionda; A Pession; A Bertaina; F Locatelli; J A McCubrey; A Cappellini; J T Barata; A M Martelli
Journal:  Leukemia       Date:  2013-11-20       Impact factor: 11.528

5.  Phlpp inhibitors block pain and cartilage degradation associated with osteoarthritis.

Authors:  Soyun M Hwang; Marina Feigenson; Dana L Begun; Lomeli Carpio Shull; Kirsty L Culley; Miguel Otero; Mary B Goldring; Lauren E Ta; Sanjeev Kakar; Elizabeth W Bradley; Jennifer J Westendorf
Journal:  J Orthop Res       Date:  2017-11-28       Impact factor: 3.494

6.  Pleckstrin Homology (PH) Domain Leucine-rich Repeat Protein Phosphatase Controls Cell Polarity by Negatively Regulating the Activity of Atypical Protein Kinase C.

Authors:  Xiaopeng Xiong; Xin Li; Yang-An Wen; Tianyan Gao
Journal:  J Biol Chem       Date:  2016-10-19       Impact factor: 5.157

7.  The tumor suppressor Mst1 promotes changes in the cellular redox state by phosphorylation and inactivation of peroxiredoxin-1 protein.

Authors:  Sonali Jalan Rawat; Caretha L Creasy; Jeffrey R Peterson; Jonathan Chernoff
Journal:  J Biol Chem       Date:  2013-02-05       Impact factor: 5.157

8.  PHLPP1 mediates melanoma metastasis suppression through repressing AKT2 activation.

Authors:  Yanlin Yu; Meng Dai; Andrew Lu; Ellen Yu; Glenn Merlino
Journal:  Oncogene       Date:  2018-02-02       Impact factor: 9.867

9.  MicroRNA-17~92 plays a causative role in lymphomagenesis by coordinating multiple oncogenic pathways.

Authors:  Hyun Yong Jin; Hiroyo Oda; Maoyi Lai; Rebecca L Skalsky; Kelly Bethel; Jovan Shepherd; Seung Goo Kang; Wen-Hsien Liu; Mohsen Sabouri-Ghomi; Bryan R Cullen; Klaus Rajewsky; Changchun Xiao
Journal:  EMBO J       Date:  2013-08-06       Impact factor: 11.598

10.  Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy.

Authors:  Hubing Shi; Willy Hugo; Xiangju Kong; Aayoung Hong; Richard C Koya; Gatien Moriceau; Thinle Chodon; Rongqing Guo; Douglas B Johnson; Kimberly B Dahlman; Mark C Kelley; Richard F Kefford; Bartosz Chmielowski; John A Glaspy; Jeffrey A Sosman; Nicolas van Baren; Georgina V Long; Antoni Ribas; Roger S Lo
Journal:  Cancer Discov       Date:  2013-11-21       Impact factor: 39.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.